InvestorsHub Logo
Followers 8
Posts 551
Boards Moderated 0
Alias Born 03/24/2020

Re: None

Thursday, 04/01/2021 7:46:40 AM

Thursday, April 01, 2021 7:46:40 AM

Post# of 18805
Aytu BioPharma Divests US Rights To Natesto To Acerus Pharma

Aytu BioPharma, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with Acerus Pharmaceuticals Corporation (ASP)(ASPCF) whereby Acerus will acquire all remaining rights to Natesto in the United States from Aytu. In consideration, Aytu will receive $7.5M in cash from Acerus, which is payable in $250,000 monthly payments over 30 months. Additionally, Acerus will assume all product responsibilities associated with Natesto following the April 1, 2021 effective date. Aytu will provide transition support to Acerus over a 120-day transition period.

Come on over to the dark side... we’ve got cookies!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AYTU News